Andere talen Opthea Limited

Aandelen

Beurs gesloten - Australian S.E. Andere beurzen 08:10:31 06-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,65 ^AUD	+5,69%		+4,00%	+14,04%

03/04	Opthea Limited kondigt wijzigingen in de Raad van Bestuur aan	CI
29/02	Opthea boekt H1 FY24-verlies per aandeel van $0,1623; R&D-uitgaven stijgen	MT

Opthea Announces Upcoming Presentations at the Retina World Congress 2024	01/05
Opthea : Quarterly Activity Report - Form 6-K	30/04
Opthea to Present at the OIS Retina Innovation Summit at ARVO	25/04
Opthea : to Present at the OIS Retina Innovation Summit at ARVO - Form 6-K	25/04
Opthea Appoints John Han, PharmD, as VP Medical Affairs	09/04
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference	05/04
Opthea Appoints Sujal Shah to the Board of Directors	03/04
Opthea Limited Announces Board Changes	03/04
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024	19/03
Opthea to Participate in the Leerink Partners Global Biopharma Conference	05/03
Opthea Posts H1 FY24 Loss per Share of $0.1623; R&D Expenses Jump	29/02
Opthea Reports Half-Year Financial Results and Business Updates	28/02
Opthea Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02
Opthea Appoints Chief Medical Advisor; Shares Decline 4%	20/02
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor	20/02
Opthea Appoints Arshad M. Khanani as Chief Medical Advisor	20/02
Opthea Concludes Enrollment in Inaugural Wet AMD Drug Trial	15/02
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept	14/02
Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept	14/02
Opthea Makes Management Appointments As Part of Next Stage Drug Trial; Shares Up 13%	02/02

Geen resultaten voor deze zoekopdracht